JP2025510591A - ｃ－Ｊｕｎアンタゴニストペプチド - Google Patents

ｃ－Ｊｕｎアンタゴニストペプチド Download PDF

Info

Publication number
JP2025510591A
JP2025510591A JP2024553833A JP2024553833A JP2025510591A JP 2025510591 A JP2025510591 A JP 2025510591A JP 2024553833 A JP2024553833 A JP 2024553833A JP 2024553833 A JP2024553833 A JP 2024553833A JP 2025510591 A JP2025510591 A JP 2025510591A
Authority
JP
Japan
Prior art keywords
amino acid
seq
jun
peptide
cjun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510591A5 (https=
JPWO2023170302A5 (https=
Inventor
メイソン，ジョディ・マイケル
ブレナン，アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Publication of JP2025510591A publication Critical patent/JP2025510591A/ja
Publication of JP2025510591A5 publication Critical patent/JP2025510591A5/ja
Publication of JPWO2023170302A5 publication Critical patent/JPWO2023170302A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024553833A 2022-03-11 2023-03-10 ｃ－Ｊｕｎアンタゴニストペプチド Pending JP2025510591A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2203399.7 2022-03-11
GBGB2203399.7A GB202203399D0 (en) 2022-03-11 2022-03-11 c-jun antagonist peptides
PCT/EP2023/056243 WO2023170302A1 (en) 2022-03-11 2023-03-10 C-jun antagonist peptides

Publications (3)

Publication Number Publication Date
JP2025510591A true JP2025510591A (ja) 2025-04-15
JP2025510591A5 JP2025510591A5 (https=) 2026-03-13
JPWO2023170302A5 JPWO2023170302A5 (https=) 2026-03-13

Family

ID=81254979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553833A Pending JP2025510591A (ja) 2022-03-11 2023-03-10 ｃ－Ｊｕｎアンタゴニストペプチド

Country Status (7)

Country Link
US (1) US20250188151A1 (https=)
EP (1) EP4490176A1 (https=)
JP (1) JP2025510591A (https=)
CN (1) CN118984835A (https=)
CA (1) CA3245706A1 (https=)
GB (1) GB202203399D0 (https=)
WO (1) WO2023170302A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118252913B (zh) * 2024-02-07 2024-09-17 中国医学科学院阜外医院 多肽偶联物及其在射血分数保留的心衰中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
US20100029552A1 (en) * 2004-08-20 2010-02-04 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
GB201820863D0 (en) 2018-12-20 2019-02-06 Univ Bath Screening assay
GB202009710D0 (en) 2020-06-25 2020-08-12 Univ Bath Cross-linking methods

Also Published As

Publication number Publication date
CA3245706A1 (en) 2023-09-14
US20250188151A1 (en) 2025-06-12
WO2023170302A1 (en) 2023-09-14
GB202203399D0 (en) 2022-04-27
CN118984835A (zh) 2024-11-19
EP4490176A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US11912794B2 (en) Modulation of structured polypeptide specificity
US11753444B2 (en) Modulation of structured polypeptide specificity
US20240294574A1 (en) Stabilized peptides for covalent binding to target protein
EP2970954A1 (en) Modification of polypeptides
JP2025510591A (ja) ｃ－Ｊｕｎアンタゴニストペプチド
EP2697249B1 (en) Compounds binding to the bacterial beta ring
Werner Structural and Functional Impacts of Chemical Modifications in Peptides and Small Proteins
HK1252864B (en) Modulation of structured polypeptide specificity
Liu Development of cyclic peptidyl ligands through a combinatorial library approach
NZ623518B2 (en) Modulation of structured polypeptide specificity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260304